Evidence map›Paper›PMID 40777841›Full record

ArticleAsian journal of pharmaceutical sciences2025

All-in-one peptide with sequential pH gradient sensing capabilities for the targeted delivery and deep penetration of nanomicelles against breast cancer.

Qinying Chen, Xinao Liu, Zijin Tan, Zhihao Liu, Zijie Qiu, Yerong Xiong, Jiasheng Tu, Yanping Wu, Chunmeng Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qinying ChenState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Dadao, Nanjing 211198, China.
Xinao LiuState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Dadao, Nanjing 211198, China.
Zijin TanState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Dadao, Nanjing 211198, China.
Zhihao LiuState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Dadao, Nanjing 211198, China.
Zijie QiuState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Dadao, Nanjing 211198, China.
Yerong XiongNMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China.
Jiasheng TuState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Dadao, Nanjing 211198, China.
Yanping WuSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 639 Longmian Dadao, Nanjing 211198, China.
Chunmeng SunState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Dadao, Nanjing 211198, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antitumor nanomedicines are usually decorated with ligands to achieve multiple functions, such as targeting delivery, tissue penetration and enhanced cellular uptake. However, a single ligand with multiple functions is generally preferred for use in practice. Herein, a versatile peptide, (HE)

Indexed as

Cell-penetrating peptidesC-end rule peptidesElectrostatic maskingPolymer micellesSequential pH sensingTargeted delivery

Identifiers

PMID40777841
PMCPMC12329104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.